OpenAI acquires a biotech start-up to accelerate AI drug development
What's the story
OpenAI has acquired Orchestra Bio, a four-year-old AI biotech software start-up. The terms of the deal have not been disclosed yet. However, it is known that the start-up had raised around $20 million by 2025 from investors such as Andreessen Horowitz, Atria, and 8VC. The acquisition will see the integration of Orchestra's team and technology into OpenAI's Rosalind, its AI model for life sciences research.
Tech integration
Orchestra Bio's expertise in AI-driven drug discovery
Orchestra Bio specializes in developing AI agents that assist biotech companies with their drug discovery operations.
These agents handle a range of tasks, from tracking finances to resolving scheduling conflicts with clinical trials.
The acquisition will see this technology integrated into OpenAI's Rosalind model as well as Rosalind Workbench, a tool designed to help researchers plan experiments and analyze results.
Clientele expansion
Enhancing the Rosalind model's reach in life sciences
The acquisition of Orchestra Bio comes as OpenAI continues to expand its Rosalind model's clientele.
The company claims that major names such as Moderna and Novo Nordisk are already using the model for life sciences research.
The integration of Orchestra's technology and team into this model is expected to further enhance its capabilities in the biotech sector.